Our Products
Opsona Therapeutics is developing a number of highly innovative products to modulate the human immune system.
Our ability to deliver is reflected in our partnerships with global companies such as Wyeth/Pfizer and CSL and investors including GenenFUND and the Novartis and Roche Venture Funds.
Our Research
Our research is focused on using targeted approaches to explore the role of Toll-Like Receptors in innate immune pathways.
A large body of recent ground breaking scientific research suggests that better understanding TLRs and TLR signalling, and applying this knowledge is an attractive, innovative approach to developing improved drugs for the treatment of autoimmune and inflammatory conditions, cancers and infectious diseases.
latest news
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
Opsona Therapeutics announces initiation of a Phase 1 clinical trial with its lead drug
candidate OPN-305, a first-in-class antibody against Toll-like-Receptor-2
Opsona Therapeutics appoints Chairman Dr. Bernd R. Seizinger as Executive Chairman; Dr. Mark Heffernan resigns as CEO but remains as Non-Executive Director
Opsona Therapeutics appoints Chairman Dr. Bernd R. Seizinger as Executive Chairman; Dr. Mark Heffernan resigns as CEO but remains as Non-Executive Director
European Commision awards EUR 5.9M to Opsona Therapeutics for clinical development of lead drug candidate OPN-305
European Commision awards EUR 5.9M to Opsona Therapeutics for clinical development of lead drug candidate OPN-305